New COVID vaccine trial targets healthy Middle-Aged adults

NCT ID NCT07279766

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Tor Biering-Sørensen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study tests whether an updated Moderna COVID-19 vaccine can prevent severe COVID-19 in adults aged 50 to 64 who have no health conditions that raise their risk. About 285,000 participants will be randomly assigned to get the vaccine or not. The main goal is to see if the vaccine reduces doctor visits or hospital stays for COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Moderna COVID-19 vaccine (updated variant formulation)
What this could lead to: If successful, this could show that healthy adults aged 50-64 benefit from an updated COVID-19 vaccine to prevent severe illness.
What could go wrong: This trial only includes people without risk factors, so results may not apply to everyone. It is also pragmatic, meaning real-world factors could affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory system disorder COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Hellerup, 2900, Denmark
Danske Lægers Vaccinations Service

Søborg, 2860, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.